Antimicrobial Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
University of Connecticut School of Pharmacy, Storrs Mansfield, Connecticut, USA.
Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0037423. doi: 10.1128/aac.00374-23. Epub 2023 May 8.
Results from this large, multicenter study suggest that patients with a confirmed ciprofloxacin, moxifloxacin, or levofloxacin hypersensitivity reaction are likely to tolerate other fluoroquinolones. Avoiding different fluoroquinolones in patients labeled with a ciprofloxacin, moxifloxacin, or levofloxacin allergy may not always be mandatory. This was a study of patients with a ciprofloxacin, moxifloxacin, or levofloxacin hypersensitivity reaction and a documented electronic medical record administration of a different fluoroquinolone. Numerically, the most common reaction risk occurred with a challenge to moxifloxacin (2/19; 9.5%), followed by ciprofloxacin (6/89; 6.3%), and levofloxacin (1/44; 2.2%).
这项大型多中心研究的结果表明，对环丙沙星、莫西沙星或左氧氟沙星过敏反应已确诊的患者可能会耐受其他氟喹诺酮类药物。避免将标签为环丙沙星、莫西沙星或左氧氟沙星过敏的患者使用不同的氟喹诺酮类药物并不总是强制性的。这是一项针对环丙沙星、莫西沙星或左氧氟沙星过敏反应患者的研究，这些患者的电子病历中有使用不同氟喹诺酮类药物的记录。从数字上看，最常见的反应风险是莫西沙星（2/19；9.5%），其次是环丙沙星（6/89；6.3%）和左氧氟沙星（1/44；2.2%）。
